Meribel selected for SABCS 2014
Last week, we informed our readers of the TRASTYVERE abstract that will be presented at SABCS.
MERIBEL is a multi-center, prospective, non-controlled phase II clinical trial to evaluate the efficacy and tolerability of first-line single-agent Eribulin in patients with HER2-negative metastatic breast carcinoma previously exposed to taxanes for early stage disease.
The primary objective of the study is to determine the median time to progression achieved with Eribulin. Other secondary objectives will be; overall response rate, clinical benefit rate, time to treatment progression, duration of response and the drug’s toxicity profile.